Advances of Nano-Structured Extended-Release Local Anesthetics

Yumiao He\textsuperscript{1,2,3}, Linan Qin\textsuperscript{2,3}, Yuguang Huang\textsuperscript{1,2*} and Chao Ma\textsuperscript{2,3*}

Abstract

Extended-release local anesthetics (LAs) have drawn increasing attention with their promising role in improving analgesia and reducing adverse events of LAs. Nano-structured carriers such as liposomes and polymersomes optimally meet the demands of extended-release, and have been utilized in drug delivery over decades and showed satisfactory results with extended-release. Based on mature technology of liposomes, EXPAREL, the first approved liposomal LA loaded with bupivacaine, has seen its success in an extended-release form. At the same time, polymersomes has advances over liposomes with complementary profiles, which inspires the emergence of hybrid carriers. This article summarized the recent research successes on nano-structured extended-release LAs, of which liposomal and polymeric are mainstream systems. Furthermore, with continual optimization, drug delivery systems carry properties beyond simple transportation, such as specificity and responsiveness. In the near future, we may achieve targeted delivery and controlled-release properties to satisfy various analgesic requirements.

Keywords: Extended-release, Local anesthetics, Nano-scale, Liposomes, Polymersome, Hybrid

Introduction

Pain has been regarded as “the fifth vital sign” since 1996 due to its significance in physical and mental health [1]. In order to deal with opioid crisis happening during traditional pain management, concept of multimodal analgesia is introduced. Local anesthetics (LAs) is one of the most frequently-used and safest analgesics in multimodal regimens [2, 3]. However, limited duration (less than 24 h) and potential toxicity (cardiac and central nervous malfunction) restrict its application and raise the urgency to counterbalance the side effects and prolonged analgesia [4–6]. Although disposable catheters with pumps are used to prolong LAs’ duration, the risks of catheter dislodgement, infection, and trauma during procedure do exist. Additionally, catheter placement is labor- and time-consuming [5]. Extended-release LAs compensate for the aforementioned disadvantages. They are capable of continuously releasing a safe dose with single administration (usually injection without general anesthesia, requiring minimal invasive techniques and special tools) to assure minimal systemic toxicity. Meanwhile, prolonged duration of nociceptive block can be achieved.

Compared to macro-scaled drug delivery systems (DDSs), nano-scaled DDS is more compatible to nano-structured biological environment which facilitates its cellular penetration, better bioavailability, and longer retention time [4]. With advances of manufacture techniques, nano-scaled DDS have achieved prominent success in extended-release, which show improved loading efficiency, better biocompatibility (acceptable local inflammation such as myotoxicity and neurotoxicity), and biodegradability (similar degradation rate with depletion of loaded compounds and assuring fully wearing off) [7–9]. Furthermore, adjustable and differentiated release profile (flexible duration, modulated analgesic intensity, and controlled targeted release by specific modifications) is designed to meet different demands [7, 8]. Furthermore, diversity of materials are available for choice nowadays, greatly decreasing the cost and expanding the application of nano-scale DDS [7]. However, nano-scaled DDS still faces drawbacks, such as burst release due to high surface-volume ratio, poor stability of liposomes on shelf, and un-ineligible foreign body response of synthetic polymers [4], all of which
attract increasing efforts to optimize nano-scaled DDS further. Here, we summarize several state-of-the art formulations of nano-structured extended-release LAs. The most commonly used morphology is nanoparticle, while nano-structured gel, niosome, film, and rod are accessible as well [8, 10, 11]. Here, synthesis techniques, release profiles, analgesic effects, and safety quality are provided and compared to help future design and development.

How Do Local Anesthetics Work?

Analgesic Mechanism and Physiochemical Properties

Peripheral nerves are the first stops to perceive pain stimuli during pain transmission [12]. It is reasonable to consider inhibiting pain from the very beginning, stopping downstream reactions and maladaptive changes of neuroplasticity which are more difficult to control [13]. Therefore, LAs become a perfect choice. LAs work on peripheral nerves via binding to intracellular domain of voltage-gated Na channel, inhibiting influx of Na⁺, resulting in the blockade of depolarization [14] (Fig. 1a, b).

LAs are constituted with three chemical groups: a hydrophilic amino group (mostly tertiary amines), a lipophilic benzene ring, and a linker which can be an amide or an ester, determining LAs’ classification (Fig. 1c). Amide-type LAs are the most commonly used, including bupivacaine, ropivacaine, lidocaine, and mepivacaine. Ester-type LAs involve chloroprocaine, procaine, and tetracaine [14, 15]. Pharmacokinetics such as speed of onset, potency, and duration are largely determined by its physicochemical properties. Permeability through neuronal membrane is a decisive factor for onset which is influenced by the equilibrium between charged and uncharged LAs. With pKa closer to extracellular pH, greater amount of uncharged LAs are formed and diffused into neurons to take effect. Potency of LAs, also called analgesic efficacy, is a result of lipophilicity, which can be quantified by the partition coefficient. Duration is a representative of protein binding affinity, which also creates a reservoir as free LAs are metabolized. Overall, ester-type LAs show relatively rapid onset due to its physiologically similar pKₐ, but short duration because of easier hydrolysis and poorer protein affinity in vivo.

He et al. Nanoscale Research Letters (2020) 15:13

Page 2 of 18

Fig. 1 Functional and Structural Properties of LAs. a, b Demonstration of how LAs interact with voltage-gated sodium channel on neuron. c Typical structures of ester and amide LAs
while bupivacaine is the LA with the longest duration of effect due to its long alky chain [14, 16] (Table 1).

Systemic Toxicity
Properties determining effects are also related with systemic toxicity. In spite of blood-brain-barrier (BBB), LAs enter central nervous system (CNS) readily with proper molecular weight, pKa, and good lipophilicity. LAs with low molecular weight, high lipid-solubility, and appropriate pKa such as lidocaine and procaine show rapid parallel change of concentration in spinal-cerebral liquid to plasma drug concentration [19]. Because LA-Na channel binding is non-exclusive, when LAs are leaked into cardiovascular system accidentally, organs with profuse blood perfusion and high activity of voltage-gated channel (Na, K, Ca), such as heart and brain, will be attacked preferably by LAs leading to organ malfunction [20, 21]. Besides the inhibition to excitation conduction of vulnerable organs, energy depletion due to mitochondrial dysfunction and apoptosis contribute as well [15, 22].

Therefore, the overall toxicity is resulted from extracellular drug concentration, cell membrane permeability, and toxic reactions induced, which can explain the more severe CNS toxicity of quaternary derivative QX-314 compared to lidocaine, although QX-314 penetrates BBB and cell membrane slower [23]. In contrast to central nervous presentations (convulsion and seizure) which are more common, but relatively easier to control, cardiac malfunction, such as conducting disturbance, arrhythmia, and contractile dysfunction, can cause deadly outcome [6, 15]. In order to prolong LAs' analgesic effect while preventing adverse events, many efforts have been put into the development of extended-release LAs.

Liposomal Formulation of Extended-Release LAs
General Ideas about Liposome
Liposome is a lipid vesicle of nanometer scale, which is phospholipid-based [10]. Liposomal techniques have been long utilized in drug delivery for treating diseases such as cancer, infection, and eye disease. Lipid has a hydrophilic head and hydrophobic tail which are linked by ester or ether bond [24]. Liposomes are produced by aggregation of lipid units in a bilayer form, creating an aqueous sheath and core with hydrophilic heads, shielding hydrophobic tails inside layers. From simple sonication to more sophisticated dry-spraying technique, increasing innovative approaches have been developed based on diverse combinations of sonication, emulsion, drying, and flow-focusing to produce liposomes with improved properties (Fig. 2) [24–28]. Thin film hydration is one of the most commonly used production techniques, while microfluidic technique is promising to scale up [29]. Drugs can be entrapped through different ways including passive loading, active loading, loading before patient use, and double emulsion (Fig. 3). Finally, drugs are carried in the aqueous core or between lipid layers depending on the drugs' hydrophilicity (Fig. 4a). This generous compatibility enables liposomes competent in delivering various drugs [24].

Several factors should be considered when building a stable and effective controlled-release system. Lipid composition is the basic and pivotal factor for designing liposomes. First of all, a stable suspension system should be assured which means no aggregation and fusion occur. Composition is the first attribute. Surface charge and electrostatic force can help liposomes repulse against each other to avoid aggregation [30]. However, suspension environment can neutralize surface charge to induce aggregation. 1,2-Dipalmitoyl-sn-glycero-3-phosphate (DPPA) and 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG) are two negatively charged lipids belonging to phosphatidylserines, which tend to aggregate when encountering calcium and magnesium cations [31]. Therefore, liposomes containing higher proportion of negatively charged lipids have a higher tendency to aggregate upon addition of divalent cations, which can help determine the lipids' proportion and concentration in liposomal suspension. With determined components, particle size is another attribute to

### Table 1 Characteristics of LAs

| Local anesthetic  | Class/chemical linkage | Onset time | Potency  | Duration of action/min |
|-------------------|------------------------|------------|----------|------------------------|
| Lidocaine         | Amide                  | Fast       | Moderate | 120 [14]               |
| Bupivacaine       | Amide                  | Slow       | Potent   | 240 [14]               |
| Ropivacaine       | Amide                  | Slow       | Potent   | 240 [17]               |
| Prilocaine        | Amide                  | Fast       | Weak     | 120 [14]               |
| Mepivacaine       | Amide                  | Fast       | Moderate | 120 [14]               |
| Articaine         | Ester                  | Fast       | Moderate | 60 [18]                |
| 2-Chloroprocaine  | Ester                  | Very Fast  | Moderate | 60 [14]                |
| Tetracaine        | Ester                  | Fast       | Moderate | 120 [14]               |
| Procaine          | Ester                  | Slow       | Weak     | 30 [14]                |
aggregation. Larger particles are more likely to aggregate in spite of net charge [30]. Besides ionic components, another environmental factor is temperature. Low temperature will put liposomes in closer proximity, inducing aggregation. Temperature slightly above transition temperature is recommended for storage [30, 32]. Another strategy to avoiding aggregation is to protect liposomes from interacting with each other by being coated with polyethyleneglycol (PEG). This hydrophilic molecule can work as a sheath, not only to prevent aggregation but also to broaden the choices of surface modification [33]. Building on this idea, improvements have been made to optimize the protection such as the addition of insulin and dextran, and PEGylated bolaamphiphile [34, 35]. Fusion needs more attraction force which is less common to happen compared to aggregation because hydration repulsion force exists when electrostatic force is absent [31]. And this form of repulsive force can be strengthened by increasing proportion of phosphatidylcholine [30, 31].

As for controlled release, decreased ratio of unsaturated lipid tails, more long-chain lipids, and ether linkers can promote stability of liposomes and slow release down. Inserting cholesterol and decorating with molecules such as PEG can also stabilize liposomes which can be classified as hybrid as described later in the review. These modifications decrease fluidity and biodegradation of liposome. Surface charge and particle size are another two considerations. Liposomes of neutral charge and smaller size are cleared more slowly [24, 36]. Octanol/buffer partition coefficient is a characteristic of actives indicating the distribution of drugs when liposomes enter physiological environment, which also determines release pattern. Drugs like bupivacaine with high octanol/buffer partition coefficient can be easily released out [16, 36].

Components not only influence physiochemical properties of liposomes but also influence physiological properties, such as tissues specificity. When liposomes enter blood circulation, phagocytosis by macrophages is the main clearance pathway. However, different recognitions by macrophages in reticuloendothelial systems (RES) happen due to different opsonization process, of which lipid composition, particle size, and surface charge are
vital determinants [37, 38]. For example, activation of complement system primarily determined by cholesterol is recognized by Kupffer cells around portal area in liver, while saturated phospholipids enhance recognition by macrophages in spleen and bone marrow [39]. Particle of larger diameter (~ 100 nm) is cleared preferentially by Kupffer cells [37, 38]. Moreover, negatively charged liposome is selectively recognized by scavenger receptor on Kupffer cell while neutral liposomes are more indolent [38]. The phagocytosis occurs rapidly, while the intracellular process is slow ranging from hours to months which results in prolonged retention in RES [37, 38]. This retention can help target RES while hindering systemic distribution. Several strategies have been developed. Morphology of filamicelle can limit the accessibility of binding sites between liposomes and receptors. Soft liposomes are less preferred by macrophages. Stealth strategy by PEGylation and CD47 modification can also passivate liposomes [40]. Saturation of macrophages (RES blockade) by extra liposomes is an alternative to extend circulation of drug-loaded liposomes [41]. In a more aggressive way, transient macrophage depletion can be performed by clodronate.

After escaping from clearance by macrophages, liposomes show good biocompatibility and bio-distribution. For tissues with high vasculature, profound blood perfusion and large vascular pore, liposomes have great tendency to enter. Tumor tissues exhibit all of the properties mentioned above. With aberrant vascular formation and lymphatic drainage, liposomes can easily enter and stay longer in tumor tissues, which is called enhanced permeability and retention (EPR) [42, 43]. Furthermore, liposomes with larger size and positive charge can overcome high interstitial fluid pressure in the center of tumor and penetrate it thoroughly [42]. Apart from passive targeting by blood transportation and structural advantages, active targeting by surface modification is also used widely to optimize selectivity, such as epidermal growth factor receptor (EGFR)-ligand and vascular endothelial growth factor (VEGF)-ligand for tumor targeting, and transferrin ligand and sphingomyelin for BBB penetration [42, 44, 45].
Multivesicular Liposome

Different packings of lipid vesicles can also help prolong drug release. Usually, liposomes are concentric where lipid membranes are packed in a multi-lamellar or uni-lamellar way (Fig. 4b, c) [16]. Therefore, collapse of internal lipid membrane will lead to drug accumulation of drug and rapid release following breach of external layer [46]. In this circumstance, sustained release cannot be achieved. Multivesicular liposomes are non-concentric where vesicles are closely packed to each other from outside (Fig. 4d). Double emulsion, which is also called DepoFoam technology, is used in the production of multivesicular liposome (Fig. 4e). Regarding multivesicular structure, at least one neutral lipid (triglyceride) and one amphipathic lipid (phospholipid) should be chosen. The percentage of triglyceride is related with drug loading efficiency within a certain range [46, 47]. It achieves longer release through gradual degradation of outermost vesicles. Multivesicular structure remains during rearrangement of internal vesicles which is isolated by outer vesicles from external environment to avoid burst release [46, 48]. Multivesicular liposomes show great dominance in release duration, which can release drug over several days to weeks through non-vascular administration compared to hours to days by uni-lamellar and multi-lamellar liposomes through intravascular route [46, 49].

Additional Advantage

Compared to other encapsulating carriers, liposomes may possess additional advantages when delivering LAs. As known by all, lipid emulsion therapy has shown its efficacy in dealing with systemic toxicity of LAs and been added into resuscitation guideline of LAs' toxicity [50]. The potential mechanisms include releasing LAs from Na\_v channels in myocardial cells, partitioning and redistributing LAs to storage (fatty acid), detoxification (liver) and excretion organs (kidney), providing extra energy, and augmenting Ca channels to strengthen cardiac output [51, 52]. Although liposomes are assumed to release bupivacaine through erosion and degradation, simultaneous diffusion through lipid membrane happen which can maintain the integrity of liposomes [16, 53, 54]. There is a research finding that large fraction of liposomes can retain its multivesicular structure even after drug is released near-completely in vitro indicating diffusion may dominate [46, 55]. Furthermore, ultrasound-induced pore formation can help remain size and structure of liposomes.

Fig. 4 Structural characteristics of different liposomes. a Drug distribution in liposomes. b Uni-lamellar liposome. c Multi-lamellar liposome. d Multi-vesicular liposome. e Demonstration of DepoFoam technique.
unchanged [56]. Therefore, assumption can be made that bupivacaine possibly shows decreased toxicity in the form of liposomes with the protection of lipids. Further researches and design manufacturing are needed to confirm and maximize this benefit.

Liposomes have been used in brain-directed drug delivery due to good biocompatibility and lipophilicity [57, 58]. There are several mechanisms mediating penetration through BBB. Transcytosis mediated by receptor or absorption is the main pathway for crossing BBB [45]. Absorption is largely determined by electrostatic attraction between liposomes and negatively charged cell membrane [45]. When liposomes are small enough, such as unilamellar liposomes encompassing lipophilic drugs, passive diffusion may occur. Modifications are also designed to strengthen ligand-receptor binding to facilitate brain-directed drug delivery [57]. Therefore, reverse designs such as negative net charge and lack of BBB-specific ligand can help prevent brain penetration and enhance safety.

**EXPAREL-First Liposomal LA Approved**

EXPAREL (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is the only extended-release liposomal LA which is approved by American Food and Drug Administration (FDA). The liposomes suspension is produced by DepoFoam technology with tricaprylin which belongs to neutral lipids, and amphipathic lipids, including 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol), 1,2-dierucoylphosphatidylcholine, and cholesterol [47, 49]. It is allowed legally in limited clinical situations, including wound infiltration which was approved in 2011, and interscalene brachial plexus block in 2018. It can achieve prolonged release and analgesic efficacy up to 72 h [5].

Compared to conventional analgesic regimen, such as free LA injection, pain pump, epidural analgesia, and patient controlled analgesia (PCA), EXPAREL has demonstrated its non-inferior analgesic potency when used through wound infiltration. Besides on-label indications, EXPAREL has also shown promising role in other analgesic routes, such as intercostal nerve block, transversus abdominis plane (TAP) block, and satellite ganglion block (Table 2). However, there are researches showing negative results on analgesic potency of EXPAREL regarding wound infiltration. These researches are different in surgeries of distinct pain intensity, also in the time-points of pain evaluation, which are relatively earlier such as 12 h. Orthopedic surgeries usually lead to severe pain in patient, therefore single wound infiltration with EXPAREL may be insufficient in controlling pain. Compared to plain bupivacaine, EXPAREL may not release adequate bupivacaine at the initial time and cannot be co-administrated with free LAs additionally to achieve better analgesia (Table 3). Therefore, analgesic effect of EXPAREL may depend on the type of surgery, pain intensity, and expected analgesic onset.

In spite of controversy in analgesia, administration route of EXPAREL is simpler and safer compared to catheter insertion, nerve block, and epidural analgesia [62, 75, 76]. In animal models, EXPAREL does not induce neurotoxicity (reduction of neuronal concentration or demyelination) after peri/intraneural or subarachnoid injection [77–79]. But EXPAREL-induced regional inflammation around injection site is higher compared to conventional bupivacaine HCl, but similar with saline [78]. Overall, EXPAREL shows similar toxicity with free bupivacaine [80–83]. Medical cost using EXPAREL decreases further compared to epidural analgesia [63, 84] and continuous pump [60], but the cost is greater than plain LAs injection [85–88]. Therefore, utilization of EXPAREL needs comprehensive considerations including different requirement of analgesia expected in different surgeries and cost-efficiency.

**Attention**

EXPAREL has an obvious restriction on application due to fluidity and rearrangement of lipid layers. Rapid release of bupivacaine with additional use of free LAs, especially within 20 min, will occur due to replacement of bupivacaine in liposomes [89]. In this circumstance, incidence of local anesthesia systemic toxicity (LAST) will increase dramatically. Lidocaine especially shows stronger affinity to DepoFoam, inducing greater systemic exposure of both lidocaine and bupivacaine when co-administered with EXPAREL within 20 min. However, the risk of burst release is not only due to replacement but also due to vascular effects of LAs and vasoconstrictors used, and diluting/mixing effects. Therefore, time beyond 20 min assures a safe level both of EXPAREL and free LAs [90]. As for bupivacaine HCl, a mixture with EXPAREL is allowed of a ratio lower than 1:2 to assure safe and sustained release [5, 49]. Since analgesia is a multi-disciplinary cooperation, careful attention should be paid to administer EXPAREL. Moreover, all liposomal products have a storage problem which is described as unstable “on the shelf.” Lipids will be degraded into harmful metabolites over a long period of storage. Excessive lysolipids and other lipid debris will bind to red blood cells resulting in deadly hemolysis. Being coated with chitosan or alginate may overcome this problem by stabilizing liposome and extending conservation up to 2 years [24, 36].

**More Inspirations**

Efforts from other points are also taken to improve liposomal bupivacaine’s analgesic efficacy. Christopher Weldon et al. increased cell-liposomal bupivacaine interaction through decreasing particular size to ten times smaller, prolonging its regional retention which achieved longer...
anesthesia and similar safety quality compared to regular liposomal bupivacaine in Bier block [91]. Changyou Zhan and his colleagues combined gold nanorods and liposomes to achieve phototriggered anesthesia. This photo-reactive system minimizes the required single dose of near-infrared light and exhibits satisfactory safety. More importantly, it achieves on-demand and repeated regional anesthesia, which will make pain management more individualized and precise [92]. Alternatively, strengthening interaction of LAs and lipids with evidence that LAs has different affinity with different lipids [93], and encapsulating liposomes with alginate to enhance anti-inflammatory reaction of mesenchymal stromal cells [94], may further improve controlled-release and meet different clinical demands.

**Polymeric Formulation of Extended-Release LAs**

**Basic Knowledge on Polymeric DDS**

Polymers are macromolecules which consist of thousands of repeated units (monomers). Unlike liposomes where Van der Waals’ force and hydrogen bonds play important roles, polymers are formed by covalent bonds, which provide better stability not only on shelf, but also when co-administered with free LAs. Large group of
biocompatible and biodegradable polymers have been used in the fabrication of extended-release material, not only natural but also synthetic. Considering different chemical properties of amide and ester LAs, corresponsive loading methods can be used to optimize loading efficiency (electrostatic interaction, covalent conjugation, and encapsulation) [8]. Additionally, flexible morphologies such as nanoparticle, nanocapsule, nanogel, nanofilm, and nanofiber expand the application of polymeric DDS in practice when injection, dressing or film is needed [7, 8]. Furthermore, structural modifications empower polymeric DDS adjustable release profile such as days for perioperative pain, weeks for chronic pain, and co-delivery with a second drug to enhance LAs’ efficacy [7]. Among the most used synthetic polymers are polyes-

| Reference Number | Route Description | Comparison Description | Surgery Description | Primary Outcome Description | Results Description |
|------------------|-------------------|------------------------|--------------------|-----------------------------|---------------------|
| [68] | Periarticular injection | Standardized cocktail | Total knee arthroplasty | VAS, total-morphine-equivalents (TME), and opioid-related-symptoms-distress-Scale (OR-SDS) at 24 and 48 h postoperatively | The LB group ($n = 52$, TME = 51.5) required significantly more narcotics than control ($n = 52$, TME = 30.03), $p = 0.025$ |
| [69] | Periarticular injection | Perioperative nerve block, ropivacaine periarticular injection | Total knee arthroplasty | Maximal NRS in intention-to-treat analysis | Median maximal pain scores were significantly lower for peripheral nerve blockade ($n = 50$) compared to LB group ($n = 52$) ($p = 0.016$) |
| [70] | Periarticular injection | Femoral nerve block | Anterior cruciate ligament reconstruction | Postoperative VAS for 4 days | A significant increase in pain in LB group ($n = 41$) between 5 and 8 h compared to control ($n = 41$) postoperatively ($6.3 \pm 2.0$ versus $4.8 \pm 2.6$, $p = 0.01$) |
| [71] | Posterior vaginal wall infiltration | Saline | Posterior vaginal wall surgery | Morphine equivalent narcotic usage; pain score on postoperative day 1, 3, 7 | No difference observed (study group $n = 49$, control group $n = 51$) |
| [72] | Parasternal nerve block | Saline | Median sternotomy for coronary revascularization | Total amount of narcotic pain medication used; patient’s pain score within the first 72 h postoperatively | No difference between two groups (study group $n = 38$, control group $n = 41$) |
| [73] | Intraoperative local infiltration | Preoperative interscalene nerve block | Shoulder arthroplasty | Postoperative average daily VAS scores for 4 days | Significant increase in pain in the LB group ($n = 26$) between 0 and 8 h postoperatively (5.3 vs. 2.5, $p = .001$) compared to control ($n = 31$) |
| [74] | Infiltration | Interscalene Block | Shoulder arthroplasty | Morphine equivalent units (MEU) consumed over the first 24 h | Similar MEU over the first 24 h; intraoperative narcotics and mean VAS pain score were significantly lower in control than in LB group (8.9 ± 4.1 vs. 16.2 ± 7.0 MEU, $p < 0.001$; at 0 h 0.8 ± 2.2 vs. 3.3 ± 2.7 points, $p < 0.001$; at 8 h 1.4 ± 2.4 vs. 3.2 ± 2.2 points; $p < 0.001$) ($n = 78$ in all groups) |

VAS visual analog scale, NRS numeric rating scale, LB liposomal bupivacaine
such as cyclodextrin and adamantane) [100, 101], esterification and ring open reaction [102–104], thiol-yne click reaction [105], and post-modification of copolymers [106]. Although this technique is mainly used in fluorescent polymeric particle recently to help protect from fluorescence-quenching and achieve aggregation-induced emission, diverse reactions and interactions make it possible that different hydrophobic drugs can find responsive polymers (especially organic polymers) to self-assemble into micelles [107, 108]. For example, secondary amide in amide LAs can be used as active moiety reacting with polymers by mannish reaction. Alternatively, drugs can be absorbed into copolymers to achieve simultaneous imaging and treatment [101]. Since hydrophobic drugs are encapsulated in the core of micelles, it can provide a suitable inner environment for drug efficacy, such as alkaline environment for LAs [107, 108]. For example, secondary amide in amide LAs can be used as active moiety reacting with polymers by mannish reaction. Alternatively, drugs can be absorbed into copolymers to achieve simultaneous imaging and treatment [101]. Since hydrophobic drugs are encapsulated in the core of micelles, it can provide a suitable inner environment for drug efficacy, such as alkaline environment for LAs.

Polymeric DDS releases active agents by several pathways. When water fluxes into polymers in the beginning, convection creates an osmotic force pumping drugs out. Yet, diffusion through pores formed in aqueous environment is the major way. It helps hydrophilic drugs, such as ionized LAs, to leak out. Contrarily, hydrophobic drugs can diffuse directly through. At the final stage of a typical tri-phase release profile, erosion of polymer dominates [111, 112].

Like liposomes, polymersomes also face the challenge of RES clearance. Morphology modification, stealth strategy, RES blockade, and macrophage depletion can be applied as well [40, 113–115]. Furthermore, the EPR effect facilitate tumor-target while auxiliary surface modification can help tissue specificity [43, 116]. Polymersomes do not induce significant systemic inflammation while some of natural polymers such as hyaluronan and laminin, and synthetic polymers such as negatively charged poly(lactic-
co-glycolic acid) and polyurethane can reduce systemic inflammatory reaction \[117–119\]. Moreover, \(N\)-(2-hydroxypropyl) methacrylamide and polystyrene are reported to reduce neurotoxicity \[120, 121\].

**Diverse Morphology and Applications**

Particle is a common form of polymeric DDS. Polymeric particles are generally divided into two categories: nanosphere and nanocapsule. Nanosphere is an evenly

| Reference Number | Polymer | LAs | Morphology | Diameter | Release profile | Analgesic efficacy |
|------------------|---------|-----|------------|----------|-----------------|-------------------|
| [122]            | Poly (\(\beta\), l-lactic acid) | Lidocaine | Nanosphere | 250–820 nm | 24–30 h | None |
| [123]            | Poly (\(\beta\), l-lactide-co-glycolide) | Procaine hydrochloride | Nanoparticle | 157.1–209.5 nm | > 6 h | None |
| [131]            | Poly (\(\beta\), l-lactide-co-glycolide) | Ropivacaine | Nanosphere | 162.7 ± 1.5 nm | None | None |
| [125]            | Alginate/bis (2-ethylhexyl)sulfosuccinate and alginate/chitosan | Bupivacaine | Nanoparticle | 926.5 ± 32 and 944.4 ± 98 nm | > 900 min | Both of study groups prolong anesthetic efficacy compared to plain bupivacaine in paw withdrawal to pressure threshold in sciatic nerve blockade (\(n = 6–7, p < 0.01\)) |
| [124]            | Poly (\(\varepsilon\)-caprolactone) | Benzocaine | Nanocapsule | 149.4–209.2 nm | None | None |
| [132]            | Poly(l-lactide) | Benzocaine | Nanocapsule | 120 nm | Up to 480 min | Prolonged the duration of analgesia in 0.006% or 0.06% benzocaine (BZC) up to 180 and 300 min respectively; increased intensity approximately twofold (\(p < 0.001\)), compared with 0.06% plain BZC in sciatic nerve block (\(n = 6–7\)) |
| [127]            | Poly (\(\varepsilon\)-caprolactone) | Lidocaine | Nanosphere | 449.6 nm | 350 min | Nanospheric lidocaine significantly (\(p < 0.001\)) increased the intensity and duration of analgesia, compared with free lidocaine in sciatic nerve block (\(n = 5\)) |
| [133]            | Alginate/chitosan | Bupivacaine | Nanoparticle | None | > 900 min | The total analgesic in infraorbital nerve blockade was improved by 1.4-fold (\(p < 0.001\)) with bupivacaine nanoparticle compared to bupivacaine (\(n = 7\)) |
| [133]            | Poly(\(\varepsilon\)-caprolactone) | Lidocaine or prilocaine | Nanocapsule | None | > 18 h | Nanocapsule showed significant increase in duration of anesthesia (\(p < 0.01\)) and the maximum possible effect (\(p < 0.01\)), compared to the commercial formulation in tail flick test (\(n = 6\)) |
| [128]            | Poly(lactide-co-glycolide) | Bupivacaine | Nanoparticle | 150 ± 10 nm | 35 days | Nanoparticle showed significant decrease on mechanically evoked response from day 1–14 days compared to blank particle |
| [134]            | N-isopropylacrylamide and acrylic acid | Bupivacaine | Gel | None | 60 days | None |
| [135]            | Tyrosine-polyethylene glycol-derived poly (ether carbonate) co-polymers and silica-based xerogel | Bupivacaine or mepivacaine | Gel | None | 7 days | Significant decrease of mechanical hypersensitivity in study group from 0.5 to 24 h compared to control and sham group (\(p < 0.05, n = 5\)) |
| [136]            | Polysaccharide | Bupivacaine | Gel | None | 120h | Significantly increased total force in study group (201.3) than LB group (144.4) to induce allodynia from 0–120 h (\(p = 0.0005, n = 20\)) |
| [129]            | Poly (lactic-co-glycolic acid) | Bupivacaine | Nanofiber (suture) | 800-1000 nm | 12 days | The greatest degree of analgesia was achieved at approximately 3 days, and significant relief was observed from 1 to 7–9 days compared to drug free suture group (\(n ≥ 6, p < 0.05\)) |
disperse system, while nanocapsule is an embedding drug in polymeric cavity [95]. The earliest researches built nanoparticles with poor entrapment efficiency (< 60%) and release duration (< 30 h) [122, 123]. With finesses of technology, the drug entrapment efficiency reaches nearly 90% [124–126], the highest result is 93.3% [127]. In-vitro release can reach a maximal duration of 35 days [128]. There is another available form termed nanofiber, which is produced by electrospinning. Electrospinning technique has been widely applied in drug delivery, but limited usage in LAs. There is one research only using electrospinning technique to fabricate bupivacaine-loaded suture. It gained satisfactory results on extended release (over 12 days), while significant analgesia appeared from day 1 to day 9 in rat skin wound model [129]. Mostly in polymersomes, drugs are entrapped physically; in polymer-drug conjugate, drug is bonded to polymer covalently to enhance drug loading capacity and prolong release furthermore [130]. Apart from solid forms, amorphous forms such as gel show more versatility and malleability. A 60-day release was seen in the work of Daryl Sivakumaran and his colleagues (Table 4) [134]. Rapid burst release over 60% of LAs was observed in the work of Haibo Qu and his colleagues (Table 4) [135].

In order to make the release intelligent, responsive materials are used in situations where structural changes, volume-phase transitions, or sol-gel transitions are needed [137]. Inflammatory reaction is a major and initial process when trauma happens. Along with it is the changes of pH and temperature. Thus, pH and temperature are stimuli used commonly in LAs delivery. In the work of Todd Hoare and his colleagues, thermal aggregation can help control regional accumulation of thermal-responsive nanogel. However, larger precipitates after aggregation induced more severe local inflammation (Table 5) [139]. Teresa Alejo and his colleagues used sequential heat pulse to trigger the collapse of nanoparticle, fastening profound release in a spatiotemporal way (Table 5) [138]. A pH-responsive polymer (methacrylic acid–ethyl acrylate) was used by Jeremy P.K. Tan to achieve decreased release of procaine chloride with decrease of pH (Table 5) [140].

Despite the advantages of being responsive to stimuli, pH and temperature-responsive polymers do not act precisely enough to localize therapeutic agents. Moreover, acidic environment and high temperature may bring harm. Therefore, stimuli which are able to modulate therapeutic agents precisely without harm are wanted. Although there is no application so far in LAs delivery, ultrasound-responsive nanoparticles exhibiting harmless property have shown precise localization in tumor targeting and imaging [141, 142]. However, ultrasound signal can be influenced by air attenuation and bone structure. Magnetic responsive nanoparticles exhibit broader application such as in respiratory system which is filled with air and central nervous system covered with cranial bone [143]. Furthermore, magnetic responsive nanoparticles can help spatially and temporally localize actives without restriction by tissues depth [143]. Generally, there are three mechanisms underlying magnetic response, which are magnetic deformation, magnetic guidance, and magnetic-induced hyperthermia [144, 145]. Aginate-based ferrogel undergoes pore formation with magnetic stimulation [146]. In contrast, chitosan-based nanoparticle undergoes pore formation with the help of heat produced by magnetic field [147, 148]. In order to decrease thermal damage to surrounding tissues, Wei Chen and his colleagues produced a core-shell structure to embed heat-producing core and prevent thermal damage [143]. The guidance function can help the nanoparticle migrate long distance and penetrate biological barrier [149]. Combination of aforementioned mechanisms can create synergistic outcomes [150].

**Table 5** Summary of researches on responsive polymeric LAs delivery system

| Reference number | Polymer | LAs | Diameter | Stimuli | Release profile | Toxicity |
|------------------|---------|-----|----------|---------|----------------|--------|
| [138]            | HGNPs@P(MEO2MA-co-OEGMA500) | Bupivacaine | 206.5 ± 49.3 nm | Heat | After 12 sequential heat pulses, the cumulative diffusive release reached a 40% in less than 8 h compared to more than 160 h at 37 °C | None |
| [139]            | Poly (N-isopropylacrylamide) | Bupivacaine | 100–1000 nm | Heat | Thermally triggered aggregation happens from 32.4 to 37.5 °C | None |
| [140]            | Methacrylic acid–ethyl acrylate (MAA-EA) | Procaine hydrochloride | 30.9–141.1 nm | pH | The percentage of procaine released at pH of 8 was ∼90% compared to ∼30% at pH of 5 | None |

HGNP Hollow gold nanoparticle
Polymeric carriers endow LAs extended-release, but unexpected burst release does exist. Long-term degradation may induce foreign body response. Versatility of materials and mature techniques are advantages of polymeric carriers. Acidic metabolites, however, may hamper the effect of LAs. Although responsive polymers make delivery more intelligent, they do not solve the aforementioned problems above completely. Therefore, further improvements are needed.

Liposomal-Polymer Hybrid Carriers of Local Anesthetic

Liposomal and polymeric nanocarriers both have drawbacks such as low solubility, poor stability, undesired drug leakage, and diffusion [151–153]. Conventional liposomes are easily cleared out by enzymatic degradation and macrophage engulfing. Therefore, surface modification with inert and hydrophilic coats, such as PEG, ganglioside GM1, and phosphatidylglycerol, have been used for protection against degradation by enzymes and macrophages. Furthermore, pegylation can enhance the negative charge of liposome and reinforce its attraction to cationic actives. In the work of Brett A. Howell and his colleagues, higher concentration and slower release of bupivacaine in human serum was observed in pegylated liposomes compared to conventional liposomes [154]. Alternatively, apolar cavity of biologically active compounds formed by cyclodextrins (a polymeric peptide), also known as an inclusion, in multi-vesicular liposomes can help achieve longer release. Inspired by various pioneer attempts to overcome drawbacks of liposome and polymeric nanoparticles, lipid-polymer hybrid nanoparticles come to the stage of controlled release [155, 156].

There are three systems of hybrid nanoparticles: lipid-core polymer-shell, polymer-core lipid-shell, and the polymer-lipid matrix. Lipid-core polymer-shell system using a polymeric coat improves the stability of liposome and delays clearance, while maintaining optimal biocompatibility of lipid core. The amphiphilic properties of some polymers can reduce surface tension of nanoparticles and decrease particle size to achieve better biocompatibility. Additionally, responsive polymers can enable liposomes more flexible behavior in various physical environment [152, 156]. Poly (acrylic acid) (Chol-PAA) is a pH-sensitive polymer, which tends to form globular structure from random coil in low pH. In poly (acrylic acid) (Chol-PAA)-caged liposome, the polymeric coat shrinks when environmental pH decreases, compressing core liposome to release significantly when liposome collapses [152]. Marina Sokolsky-Papkov and her colleagues used hybrid polymer (DL-lactic acid and castor oil) to formulate bupivacaine-loaded nanoparticles. This poly (fatty-ester) achieved relatively longer in-vitro release (beyond 1 week) and sensory blockade (>72 h) compared to previous research [157]. Further research confirmed its release profile and extended its analgesic efficacy among thermal pain, mechanical pain, and rearing assessment [158]. Another research study explored the difference between oil nucleus on stability, release profile, and analgesia property, and found that a higher entrapment efficacy was observed compared to polymeric DDS [159].

Polymer-core lipid-shell system is commonly used in intravenous administration of drugs, especially anticancer drugs [151, 155]. The two components together help inhibit water infiltration and slow hydrolysis down, and as a result prevent drug diffusion and burst leakage. Lipid shell also enhances biocompatibility of nanoparticle with similarity to cell membrane [160]; this is promising in achieving simultaneous co-delivery of multiple drugs [151, 152, 160]. On the other hand, polymeric core can facilitate mechanical stability, shape control, and size distribution. Additionally, it can increase drug entrapment efficacy. In the work of Jianguo Wang and his colleagues, nanoparticle showed a slower release speed, smaller particle diameter, and higher drug loading compared to traditional liposomes [161]. The work by Pengju Ma et al. showed that hybrid bupivacaine nanoparticle had better stability, analgesic efficacy, and cytotoxicity [162].

The third system is a polymer-lipid matrix which can be subdivided into polymerized liposomes and nano-in-micro type. As their names suggest, polymerized liposome is a covalently bound liposome which demonstrates better stability and modulated release as mentioned above with basic knowledge on polymeric DDS [154], while the nano-in-micro system gathers nanoparticles into a matrix to achieve controlled release as shown in the work of Khanal Manakamana and his colleagues [163]. Moreover, hybrid nanoparticle was used in transdermal route showing better skin permeation than free bupivacaine in three studies by Yaocun Yue and Aimei Li et al., which expands its clinical application of analgesia [161, 164, 165].

Future Perspectives

Nano-structured systems have been utilized in extended-release for drug delivery over decades. Tremendous breakthroughs have been seen in controlled release of LAs to achieve longer duration of analgesic and better safety profile, bringing in the successful approval of EXPAREL. At the same time, various modifications and combinations of nano-structured systems have broaden the horizon of LAs. With the guidance of physical or chemical stimuli, targeting LAs to treat the specific sources of pain may not be a difficult process anymore. Additionally, with the help of external and internal stimulus, we may modulate the release profile of LAs even after administration. Physiochemical properties of actives, rather than carriers alone, are also taken into
account to formulate new and flexible systems. In the future, we may see precisely designed extended-release LAs to meet different demands of analgesic intensity, duration, and target sites in distinct surgeries, to make analgesia more individualized.

Conclusions

LAs are key components in multimodal analgesia. Short duration and adverse side effects limit its application, which induces the emergence of extended-release LAs. Nano-structured DDSs show better biocompatibility and biodegradation compared to micro-structured DDSs due to similar size with physiological environment. Among various nanocarriers, liposomes achieve the first success in super-long-lasting LAs, which can release bupivacaine for 72 h in vivo. Liposomes also potentiate the safety of LAs with the protection of emulsion. The instability of liposome, however, hinders its storage and co-administration profile with additional free LAs. Compared to liposome, polymersome has a more advantageous profile with better stability and prolonged release. Moreover, the electrospinning technique and the stimuli-responsive property endow polymersomes with more flexibility in morphology and release behavior. Besides the optimization of materials and manufacturing processes, combination of nanocarriers is an alternative way to improve drawbacks and boost strengths. This is where hybrid nanocarriers come to the stage: hybrids not only improve the release profile but also broaden administration routes, such as the transdermal route. With the ever-emerging versatility of nanocarriers, extended-release may become more specific and controllable in the future to satisfy various analgesic demands.

Abbreviations

BBB: Blood-brain barrier; CNS: Central nervous system; DDSs: Drug delivery systems; DPDA: 1,2-Dipalmitoyl-sn-glycero-3-phosphate; DSGF: 1,2-Distearoyl-sn-glycero-3-phosphate(1-rac-glycerol); EGR: Epidermal growth factor receptor; EPR: Enhanced permeability and retention; FDA: American Food and Drug Administration; LAs: Local anesthetics; LAST: Local anesthesia systemic toxicity; PCA: Patient controlled analgesia; PEG: Polyethylene glycol; PRINT: Particle replication in nonwetting template; RES: Reticuloendothelial system; TAP: Transversus abdominis plane; VEGF: Vascular endothelial growth factor

Acknowledgments

Not applicable.

Authors' Contributions

YH made substantial contributions to the conception, paper collecting, and analyzing of the work; and drafting the work; and final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. CM made substantial contributions to conception of the work; and revising it critically for important intellectual content; and final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding

National Natural Science Foundation of China (NSFC #81771205, #91632113), the Natural Science Foundation and Major Basic Research Program of Shanghai (16JC1420500, 16JC1420502), and the CAMS Innovation Fund for Medical Sciences (CIFMS #2017-I2M-5-008).

Availability of Data and Materials

Not applicable.

Competing Interests

The authors declare that they have no competing interests.

Author details

1Department of Anesthesiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. 2Joint Laboratory of Anesthesia and Pain, Peking Union Medical College, Beijing 100730, China. 3Department of Human Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China.

Received: 2 July 2019 Accepted: 26 December 2019

Published online: 16 January 2020

References

1. Levy N, Strugess J, Mills P (2018) "Pain as the fifth vital sign" and dependence on the "numerical pain scale" is being abandoned in the us: Why? Br J Anaesth 120:435–438
2. Rawal N (2016) Current issues in postoperative pain management. Eur J Anaesthesiol 33:160–171
3. Helander EM, Menard BL, Harmon CM, Homra BK, Allain AV, Bordelon CJ et al (2017) Multimodal analgesia, current concepts, and acute pain considerations. Curr Pain Headache Rep 21:3
4. Zorzetto L, Brambilla P, Marcello E, Bliese N, De Gregori M, Cobianchi L et al (2016) From micro- to nanostructured implantable device for local anesthetic delivery. Int J Nanomedicine 11:2695–2709
5. Balocco AL, Van Zundert PGE, Gan SS, Gan TJ, Hadzic A (2018) Extended release bupivacaine formulations for postoperative analgesia. Curr Opin Anaesthesiol 31:1110–1119
6. El-Boghdadly K, Pawa A, Chin KJ (2018) Local anesthetic systemic toxicity: Current perspectives. Local Reg Anesth 11:35–44
7. Santamaria CM, Woodruff A, Yang R, Kohane DS (2017) Drug delivery systems for prolonged duration local anesthesia. Mater Today (Kidlington) 2022–31
8. Venditti I (2019) Morphologies and functionalities of polymeric nanocarriers as chemical tools for drug delivery: A review. J King Saud University - Science 31:398–411
9. Andreu V, Armuño M (2018) Current progress and challenges of nanoparticle-based therapeutics in pain management. J Control Release 269:189–213
10. Moradiharni MR, Karimi A, Negahdari B (2018) Nanotechnology application to local anaesthesia (LA). Antif Cells Nanomed Biotech 46:355–360
11. Rinaldi F, Del Favero E, Moeller J, Hanieh PN, Passeri D, Rossi M et al (2019) Hydrophilic silver nanoparticles loaded into niosomes: Physical-chemical characterization in view of biological applications. Nanomaterials (Basel) 9
12. Bradford W, Fenton ES, Zolton J (2015) The neurobiology of pain perception: Dependence on the ever-emerging versatility of nanocarriers, extended-administration routes, such as the transdermal route. With the ever-emerging versatility of nanocarriers, extended-release may become more specific and controllable in the future to satisfy various analgesic demands.
63. Medina M, Foiles SR, Francois M, Asche CV, Rein J, Mueller DK et al (2019) Comparison of cost and outcomes in patients receiving thoracic epidural versus liposomal bupivacaine for video-assisted thoracoscopic pulmonary resection. Am J Respir Crit Care Med 201:520–524

64. Bhakta A, Glotzer O, Ata A, Tafem M, Stan SC, Singh PT (2018) Analgesic efficacy of laparoscopic-guided transverse abdominal plane block using liposomal bupivacaine in bariatric surgery. Am J Surg 215:643–646

65. Gatherwright J, Knackstedt RW, Ghaemavi AM, Bernard S, Schwarz G, Moreira A et al (2018) Prospective, randomized, controlled comparison of bupivacaine versus liposomal bupivacaine for pain management after unilateral delayed deep inferior epigastric perforator free flap reconstruction. Plast Reconstr Surg 141:1237–1330

66. Ayad S, Babaeazad R, Elsharkawy H, Nadar V, Lokhande C, Makarova N et al (2018) Comparison of transversus abdominis plane infiltration with liposomal bupivacaine versus continuous epidural analgesia versus intravenous opioid analgesia. PLoS One 11:e0153675

67. Hutchins JL, Kesha R, blanco F, Dumn T, Hochhalter R (2016) Ultrasound-guided subcostal transversus abdominis plane blocks with liposomal bupivacaine versus non-liposomal bupivacaine for postoperative pain control after laparoscopic hand-assisted donor nephrectomy: a prospective randomised observer-blinded study. Anaesthesia. 71:930–937

68. Suarez JC, Al-Mansoori AA, Kanwar S, Semien GA, Villa JM, CA MN et al (2018) Liposomal bupivacaine vs liposomal bupivacaine in the porcine model of sciatic nerve block. J Arthroplast 33:97–101

69. Jones CL, Gruber DD, Fischer JR, Leonard K, Hernandez SL (2018) Liposomal bupivacaine versus interscalene nerve block for pain control after anterior cruciate ligament reconstruction: a prospective, double-blind, placebo-controlled trial. J Arthroplast 33:97–101

70. Okoroha KR, Keller RA, Marshall NE, Jung EK, Mehran N, Owashi E et al (2018) Liposomal bupivacaine versus femoral nerve block for pain control after anterior cruciate ligament reconstruction: a prospective randomized trial. J Arthroplast 33:97–101

71. Tsuchiya H, Ueno T, Mizogami M, Takakura K (2010) Local anesthetics and functions. Chem Rev 109:5799–5867

72. Premkumar A, Samady H, Stone H, Rassar S, Xerogeanes J (2016) Liposomal bupivacaine for pain control after anterior cruciate ligament reconstruction: a prospective, double-blind, randomized, positive-controlled trial. Am J Sports Med 44:1680–1686

73. Krantonov V (2014) A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials. Postgrad Med 126:129–138

74. Okoroha KR, Lynch JR, Keller RA, Korona J, Rill B et al (2016) Multivesicular liposomal bupivacaine at the sciatic nerve. Reg Anesth Pain Med 40:572–581

75. Amundson AW, Johnson RL, Abdel MP, Mantilla CB, Panchamia JK, Taunton MJ et al (2014) Multivesicular liposomal bupivacaine in bariatric surgery. J Bone Joint Surg Am 96:550–556

76. Aquino AC, Schmitz-Feuerhake K, de Assis AP, de Almeida P, de Freitas L, Tessa P et al (2018) Incidence of adverse events attributable to liposomial bupivacaine injectable suspension or plain bupivacaine for postoperative pain in pediatric surgical patients: a retrospective matched cohort analysis. Paediatr Anaesth 29:169–174

77. Aggarwal N (2018) Local anesthetics systemic toxicity association with exparel (bupivacaine liposome): a pharmacovigilance evaluation. Expert Opin Drug Saf 17:581–587

78. Springer BD, Mason JB, Odum SM (2018) Systemic safety of liposomal bupivacaine in simultaneous bilateral total knee arthroplasty. J Arthroplast 33:97–101

79. Ifteld BM, Viscusi ER, Hadzic A, Minkowitz HS, Morren MD, Lookabbaugh J et al (2015) Safety and side effect profile of Liposome bupivacaine (exparel) in peripheral nerve blocks. Reg Anesth Pain Med 40:572–582

80. Felling DR, Jackson MW, Ferraro J, Battaglia MA, Albright JJ, Wu J et al (2018) Liposomal bupivacaine transversus abdominis plane block versus epidural analgesia in a colon and rectal surgery enhanced recovery pathway: a randomized clinical trial. Dis Colon Rectum 61:1196–1204

81. Danoff JR, Goel R, Henderson RA, Fraser J, Sharkey FA (2018) Periarticular ropivacaine cocktail is equivalent to liposomal bupivacaine cocktail in bilateral total knee arthroplasty. J Arthroplast 33:2455–2459

82. Zlobicki JP, Hamlin BR, Pialeychuk AY, Levison TJ, Rothenberger SD, Urish KL (2018) Liposomal bupivacaine vs plain bupivacaine in periarticular injection for control of pain and early motion in total knee arthroplasty: a randomized, prospective study. J Arthroplast 33:2460–2464

83. Hyland SJ, Deliberato DG, Fada RA, Romanelli M, Collins CL, Waisielewski RC (2019) Liposomal bupivacaine versus standard periarticular injection in total knee arthroplasty with regional anesthesia: a prospective randomized controlled trial. J Arthroplast 34:488–494

84. Okoroha KR, Lynch JR, Keller RA, Korona J, Rill B et al (2016) Liposomal bupivacaine versus interscalene nerve block for pain control after anterior cruciate ligament reconstruction: a prospective, double-blind, randomized, positive-controlled trial. Am J Sports Med 44:1680–1686

85. Tsuchiya H, Ueno T, Mizogami M, Takakura K (2010) Local anesthetics structure-dependently interact with anionic phospholipid membranes to modify the fluidity. Chem Biol Interact 183:19–24

86. Davis MS, Rames-Roers-Isti Perez XI, Maguire T, Radhakrishnan P, Manchikapatla D et al (2017) Liposomal-bupivacaino construct for bupivacaine delivery and muc function regulation. Drug Deliv Transl Res 8:226–238

87. El-Say KM, El-Sawy HS (2017) Polymeric nanoparticles: Promising platform for drug delivery. Int J Pharm 528:675–691

88. Swider E, Koshinka O, Tel J, Cruz LJ, de Vries UM, Sinivas M (2018) Customizing poly(actic-co-glycolic acid) particles for biomedical applications. Acta Biomater 73:38–51

89. Jiang R, Liu H, Liu M, Tian J, Huang Q, Huang H et al (2017) A facile one-pot mannich reaction for the construction of fluorescent polymer nanoparticles with aggregation-induced emission feature and their biological imaging. Mater Sci Eng C Mater Biol Appl 73:181–186

90. Liu J, Lam J, Yang B (2009) Acetylenic polymers- synthesis, structures, and functions. Chem Rev 109:5799–5867

91. Jiang R, Liu M, Li C, Huang Q, Huang H, Wan Q et al (2017) Facile fabrication of luminescent polymer nanoparticles containing dynamic linkages via a one-pot multicomponent reaction synthesis, aggregation-induced emission and biological imaging. Mater Sci Eng C Mater Biol Appl 78:507–714

92. Huang H, Xu D, Liu M, Jiang R, Mao L, Huang Q et al (2017) Direct encapsulation of a novel active dye with beta cyclodextrin terminated polymers: self-assembly and biological imaging. Mater Sci Eng C Mater Biol Appl 78:862–867

93. Huang H, Liu M, Jiang R, Chen J, Mao L, Wen Y et al (2018) Facile modification of nanodiamonds with hyperbranched polymers based on supramolecular chemistry and their potential for drug delivery. J Colloid Interface Sci 513:198–204
102. Long Z, Liu M, Wang K, Deng F, Xu D, Liu L et al (2016) Facile synthesis of
103. aie-active amphiphilic polymers: Self-assembly and biological imaging
104. applications. Mater Sci Eng C Mater Biol Appl 66:215–220
105. Tian J, Jianger R, Gao P, Xu D, Ma L, Zeng G et al (2017) Synthesis and cell
106. imaging applications of amphiphilic aie-active poly(amino acids). Mater Sci
107. Eng C Mater Biol Appl 79:563–569
108. Huang L, Yang S, Chen J, Tian J, Huang Q, Huang H et al (2019) A facile
109. surface modification strategy for fabrication of fluorescent silica
110. nanoparticles with the aggregation-induced emission dye through surface-
111. initiated cationic ring opening polymerization. Mater Sci Eng C 94:270–278
112. Cao QT, Jianger R, Liu M, Wan Q, Xu D, Tian J et al (2017) Preparation of aie-
113. active fluorescent polymeric nanoparticles through a catalyst-free thiol-yne
114. click reaction for bioimaging applications. Mater Sci Eng C Mater Biol Appl
115. 80:411–416
116. Liu Y, Mao L, Liu X, Liu M, Xu D, Jiang R et al (2017) A facile strategy for
117. fabrication of aggregation-induced emission (aie) active fluorescent
118. polymeric nanoparticles (fps) via post modification of synthetic polymers
119. and their cell imaging. Mater Sci Eng C Mater Biol Appl 79:590–595
120. Zhang X, Wang K, Liu M, Zhang X, Tao L, Chen Y et al (2015) Polymeric
121. aie-based nanoprobes for biomedical applications—recent advances and
122. perspectives. Nanoscale 7:11486–11508
123. Wan Q, Huang Q, Li M, Xu D, Huang H, Zhang X et al (2017) Aggregation-
124. induced emission active luminescent polymeric nanoparticles: non-covalent
125. fabrication methodologies and biomedical applications. Appl Mater Today
126. 9:145–160
127. Cao Q, Jianger R, Liu M, Wan Q, Xu D, Tian J et al (2017) Microwave-assisted
128. multicomponent reactions for rapid synthesis of aie-active fluorescent
129. polymeric nanoparticles by post-polymerization method. Mater Sci Eng C
130. Mater Biol Appl 80:578–583
131. Jiang R, Liu M, Huang H, Mao L, Huang Q, Wen Y et al (2018) Facile
132. fabrication of organic dyed polymer nanoparticles with aggregation-
133. induced emission using an ultrasound-assisted multicomponent reaction
134. and their biological imaging. J Colloid Interface Sci 519:137–144
135. Fredenborg S, Wahlgren M, Rieslow M, Axelsson A (2011) The mechanisms
136. of drug release in poly(lacto-co-glycolic acid)-based drug delivery
137. systems—a review. Int J Pharm 415:34–52
138. Zlomke C, Barth M, Mader K (2019) Polymer degradation induced drug
139. precipitation in plga implants - why less is sometimes more. Eur J Pharm
140. Biopharm 139:142–152
141. Wang CE, Stayton PS, Sun SH, Convertine AJ (2015) Polymer nanostructures
142. synthesized by controlling living polymerization for tumor-targeted drug
143. delivery. J Control Release 219:345–354
144. Liu Y, Ye Q, Lu M, Lo YC, Hsu YH, Wei MC et al (2015) A new approach to
145. reduce toxicities and to improve bioavailabilities of platinum-containing
146. anti-cancer nanodrugs. Sci Rep 5:10881
147. Mozar FS, Chowdhury EH (2018) Pegylation of carbonate apatite
148. nanocomposites. J Control Release 214:2508–2519
149. Liu L, Ye Q, Lu M, Lo YC, Hsu YH, Wei MC et al (2015) A new approach to
150. reduce toxicities and to improve bioavailabilities of platinum-containing
151. anti-cancer nanodrugs. Sci Rep 5:10881
152. Hutchins J, Taylor W (2017) An evaluation of the analgesic effect of
153. Thermoresponsive nanogels—A new approach to reduce toxicities and to
154. improve bioavailabilities of platinum-containing anti-cancer nanodrugs. Sci Rep 5:10881
155. Mozar FS, Chowdhury EH (2018) Pegylation of carbonate apatite
156. nanocomposites. J Control Release 214:2508–2519
157. Bagshaw KR, Hanenbaum CL, Carbonie EJ, Lo KW, Laurencin CT, Walker J et al (2015) Pain management via local anesthetics and responsive hydrogels. Ther Deliv 6:165–176
158. Alejo T, Andreu V, Mendoza G, Sebastian V, Amuebo M (2018) Controlled release of bupivacaine using hybrid theremoresponse nanocapsules activated via photothermal heating. J Colloid Interface Sci 523:234–244
159. Hoare T, Young S, Lawlor MW, Kohane DS (2012) Theremoresponse nanocapsules for prolonged duration local anesthetica. Acta Biomater 8:3596–3605
160. Tan JP, Goh CH, Tam KC (2007) Comparative drug release studies of two cationic drugs from ph-responsive nanocapsules. Eur J Pharm Sci 33:729–738
161. Pugazhenthi S, Kondratiuk P, Assadi S, Bhatia A, Parveen M, Ghalib B (2015) Injectable microgel-hydrogel composites for prolonged small-molecule drug delivery. Polymer 65:1421–1430
162. Hu Q, Costache MC, Inan S, Cowan D, Devuche P (2015) Local, controlled delivery of local anesthetics in vivo from polymer—xerogel composites. Pharm Res 33:729–738
163. Chagpar A, Hammad N, Al-Mahroos M, Khater IA, Al-Deyab S, El-Tahan A (2015) Controlled release of bupivacaine using hybrid theremoresponse nanocapsules activated via photothermal heating. J Colloid Interface Sci 523:234–244
164. Hoare T, Young S, Lawlor MW, Kohane DS (2012) Theremoresponse nanocapsules for prolonged duration local anesthetica. Acta Biomater 8:3596–3605
165. Tan JP, Goh CH, Tam KC (2007) Comparative drug release studies of two cationic drugs from ph-responsive nanocapsules. Eur J Pharm Sci 33:729–738
166. Cavaill D, Ragnonzano M, Vigna E, Giustinetti P, Torres E, Aime S et al (2015) Preparation and in vitro characterization of chitosan nanobubbles as thermoanagentic carriers. Colloids Surf B: Biointerfaces 129:39–46
167. Jing Y, Zhu Y, Yang X, Shen L, Li C (2011) Ultrasound triggered smart drug release from multifunction core-shell capsules one-step fabricated by coaxial electrospray method. Langmuir 27:1715–1780
168. Chen W, Cheng CA, Zink JI (2019) Spatial, temporal, and dose control of drug delivery using noninvasive magnetic stimulation. ACS Nano 13:12922–1308
147. Wang H, Mu Q, Revia R, Wang K, Zhou X, Pauzauskie PJ, and et al. Chitosan- 
gated magnetic-responsive nanocarrier for dual-modal optical imaging, 
switchable drug release, and synergistic therapy. Adv Healthc Mater. 2017;6.
148. Mohapatra A, Harris MA, LeVine D, Ghimire M, Jennings JA, Monshid Bl et al 
(2018) Magnetic stimulus responsive vancomycin drug delivery system 
based on chitosan microbeads embedded with magnetic nanoparticles. J 
Biomed Mater Res B Appl Biomater 106:2169–2176
149. Wu X, Yang H, Yang W, Chen X, Gao J, Gong X et al (2019) Nanoparticle- 
based diagnostic and therapeutic systems for brain tumors. J Mater Chem B 
7:4734–4750
150. Chiang CS, Shen YS, Liu JJ, Shyu WC, Chen SY (2016) Synergistic 
combination of multistage magnetic guidance and optimized ligand 
density in targeting a nanoplatfrom for enhanced cancer therapy. Adv 
Healthc Mater 5:2131–2141
151. Garg NK, Tandel N, Jardon RS, Tyagi RK, Katare OP (2018) Lipid-polymer 
hybrid nanocarrier-mediated cancer therapeutics: current status and future 
directions. Drug Discov Today 23:1610–1621
152. Rao S, Prestidge CA (2016) Polymer-lipid hybrid systems: merging the 
benefits of polymeric and lipid-based nanocarriers to improve oral drug 
delivery. Expert Opin Drug Deliv 13:691–707
153. Sgorla D, Bunhak Ej, Cavalcanti OA, Fonte P, Sarmento B (2016) Exploitation 
of lipid-polymeric matrices at nanoscale for drug delivery applications. 
Expert Opin Drug Deliv 13:1301–1309
154. Howell BA, Chauhan A (2009) Bupivacaine binding to pegylated liposomes. 
Anesth Analg 109:678–682
155. Rose RJC, Ravikumar R, Kuntegouder V, Benett D, Rangasamy S, 
Thandavaran RA (2017) Lipid-polymer hybrid nanoparticle-mediated 
therapeutics delivery: advances and challenges. Drug Discov Today 22: 
1258–1265
156. Tellevita MC, Carbone C, Souto EB (2017) Beyond liposomes: recent 
advances on lipid based nanostructures for poorly soluble/poorly 
permeable drug delivery. Prog Lipid Res 68:1–11
157. Sokolovs-Papkov M, Golovanetski L, Domb AJ, Weiniger CF (2011) Long- 
acting poly(DLactic acid-castor oil) 3:7-bupivacaine formulation: Effect of 
hydrophobic additives. Pharm Res 28:3265–3273
158. Ickowicz DE, Golovanetsk L, Domb AJ, Weiniger CF (2014) Extended 
duration local anesthetic agent in a rat paw model. Int J Pharm 468:152– 
157
159. de Melo NF, Grillo R, Guilherme VA, de Araujo DR, de Paula E, Rosa AH 
(2011) and at el. Poly(lactide-co-glycolide) nanocapsules containing 
benzocaine: Influence of the composition of the oily nucleus on physico- 
chemical properties and anesthetic activity. Pharm Res 28:1984–1994
160. Li Q, Cai T, Huang Y, Xia X, Cole SFC, Cai Y. A review of the structure, 
preparation, and application of nlcs, pnps, and plns. Nanomaterials (Basel). 
2017;7
161. Wang J, Zhang L, Chi H, Wang S (2016) An alternative choice of lidocaine- 
loaded liposomes: Lidocaine-loaded lipid-polymer hybrid nanoparticles for 
local anesthetic therapy. Drug Deliv 23:1254–1260
162. Ma P, Li T, Xing H, Wang S, Sun Y, Sheng X et al (2017) Local anesthetic 
effects of bupivacaine loaded lipid-polymer hybrid nanoparticles: in vitro 
and in vivo evaluation. Biomed Pharmacother 89:689–695
163. Khanal M, Gohil SV, Kuyinu E, Kan H-M, Knight BE, Baumbauer KM et al 
(2018) Injectable nanocomposite analgesic delivery system for 
musculoskeletal pain management. Acta Biomater 74:280–290
164. Yue Y, Zhao D, Yin Q (2018) Hyaluronic acid modified nanostructured lipid 
carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia 
evaluation. Biomed Pharmacother 98:813–820
165. Li A, Yang F, Xin J, Bai X (2019) An efficient and long-acting local anesthetic: 
Ropivacaine-loaded lipid-polymer hybrid nanoparticles for the control of 
pain. Int J Nanomedicine 14:913–920

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.